Abstract
Oxaliplatin(Elplat(®)iv infusion solution)is a third-generation 1,2-DACH-platinum derivative. A number of international clinical trials have investigated the effects of this drug for each of its four indications. Building on the results of these earlier studies, much research has also been carried out in Japan in terms of developing and accumulating evidence on oxaliplatin. This report reviews the trajectory of its use over the last 10-years and considers its future potential.
| Original language | English |
|---|---|
| Pages (from-to) | 715-722 |
| Number of pages | 8 |
| Journal | Gan to kagaku ryoho. Cancer & chemotherapy |
| Volume | 43 |
| Issue number | 6 |
| Publication status | Published - Jun 1 2016 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
Oxaliplatin -- A 10-Year Trajectory. / Kanaji, Shingo; Oki, Eiji; Saeki, Hiroshi; Kitao, Hiroyuki; Maehara, Yoshihiko; Kakeji, Yoshihiro.
In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 43, No. 6, 01.06.2016, p. 715-722.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oxaliplatin -- A 10-Year Trajectory
AU - Kanaji, Shingo
AU - Oki, Eiji
AU - Saeki, Hiroshi
AU - Kitao, Hiroyuki
AU - Maehara, Yoshihiko
AU - Kakeji, Yoshihiro
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Oxaliplatin(Elplat(®)iv infusion solution)is a third-generation 1,2-DACH-platinum derivative. A number of international clinical trials have investigated the effects of this drug for each of its four indications. Building on the results of these earlier studies, much research has also been carried out in Japan in terms of developing and accumulating evidence on oxaliplatin. This report reviews the trajectory of its use over the last 10-years and considers its future potential.
AB - Oxaliplatin(Elplat(®)iv infusion solution)is a third-generation 1,2-DACH-platinum derivative. A number of international clinical trials have investigated the effects of this drug for each of its four indications. Building on the results of these earlier studies, much research has also been carried out in Japan in terms of developing and accumulating evidence on oxaliplatin. This report reviews the trajectory of its use over the last 10-years and considers its future potential.
UR - http://www.scopus.com/inward/record.url?scp=84982787182&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982787182&partnerID=8YFLogxK
M3 - Article
C2 - 27306807
VL - 43
SP - 715
EP - 722
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
SN - 0385-0684
IS - 6
ER -